Published in Curr Gene Ther on June 01, 2006
Region-specific genetic alterations in the aging hippocampus: implications for cognitive aging. Front Aging Neurosci (2010) 0.92
From neuroanatomy to gene therapy: searching for new ways to manipulate the supraspinal endogenous pain modulatory system. J Anat (2007) 0.81
Viral vector-mediated blockade of the endocrine stress-response modulates non-spatial memory. Neurosci Lett (2008) 0.79
Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice. Curr Protoc Neurosci (2015) 0.76
Functional interaction between class II histone deacetylases and ICP0 of herpes simplex virus type 1. J Virol (2004) 1.59
Determination of minimum herpes simplex virus type 1 components necessary to localize transcriptionally active DNA to ND10. J Virol (2003) 1.15
N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J Neurochem (2010) 1.10
Nucleolin is required for an efficient herpes simplex virus type 1 infection. J Virol (2008) 1.07
Nucleolin interacts with US11 protein of herpes simplex virus 1 and is involved in its trafficking. J Virol (2011) 0.94
Herpes simplex virus type 1 ICP0 protein mediates activation of adeno-associated virus type 2 rep gene expression from a latent integrated form. J Virol (2004) 0.92
Definition of herpes simplex virus type 1 helper activities for adeno-associated virus early replication events. PLoS Pathog (2009) 0.89
The structures of bovine herpesvirus 1 virion and concatemeric DNA: implications for cleavage and packaging of herpesvirus genomes. Virology (2003) 0.88
Infection with herpes simplex type 1-based amplicon vectors results in an IRF3/7-dependent, TLR-independent activation of the innate antiviral response in primary human fibroblasts. J Gen Virol (2009) 0.87
Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J Gene Med (2010) 0.87
Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther (2003) 0.85
Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics. Mol Cell Proteomics (2008) 0.84
Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol (2005) 0.84
Identification of rep-associated factors in herpes simplex virus type 1-induced adeno-associated virus type 2 replication compartments. J Virol (2010) 0.83
HSV-1 Cgal+ infection promotes quaking RNA binding protein production and induces nuclear-cytoplasmic shuttling of quaking I-5 isoform in human hepatoma cells. Mol Cell Proteomics (2011) 0.82
Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver Int (2011) 0.82
HSV as a vector in vaccine development and gene therapy. Hum Vaccin (2008) 0.81
Characterization of antiproliferative and cytotoxic properties of the HSV-1 immediate-early ICPo protein. J Gene Med (2005) 0.81
HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther (2007) 0.81
HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice. Mol Ther (2012) 0.81
Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft. J Proteomics (2009) 0.80
HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol (2009) 0.80
Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J Gene Med (2004) 0.80
Herpes simplex virus type 1-derived recombinant and amplicon vectors. Methods Mol Biol (2011) 0.78
Factors influencing helper-independent adeno-associated virus replication. Virology (2012) 0.77
Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1. J Mol Cell Cardiol (2004) 0.77
Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol (2004) 0.77
HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr Opin Drug Discov Devel (2010) 0.77
Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. J Gen Virol (2002) 0.76
Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors. Methods Mol Biol (2014) 0.76
Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors for gene transfer and gene therapy. Methods Mol Biol (2015) 0.76
Herpes simplex virus type 1 (HSV-1)-derived recombinant vectors for gene transfer and gene therapy. Methods Mol Biol (2015) 0.76
Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther (2015) 0.75
Induction of humoral responses to BHV-1 glycoprotein D expressed by HSV-1 amplicon vectors. J Vet Sci (2012) 0.75
Constitutive and Inducible Innate Responses in Cells Infected by HSV-1-Derived Amplicon Vectors. Open Virol J (2010) 0.75
Expression of human papilloma virus type 16 antigens, specific targeting as well as formation of virus-like particles by HSV-1 amplicon vectors. Virus Genes (2008) 0.75
Present and future of herpes simplex virus type 1 (HSV-1)-based amplicon vectors. Pathol Biol (Paris) (2005) 0.75